DuChemBIO Co.,Ltd. announced that it has received KRW 2 billion in funding from Asam Asset Management Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm
March 11, 2018
Share
DuChemBIO Co.,Ltd. (XKON:A176750) announced a private placement of 6th series unregistered coupon unguaranteed private convertible bonds for gross proceed of KRW 2,000,000,000 on March 12, 2018. The transaction included participation from new investors, Asam Asset Management Co., Ltd. for KRW 1,500,000,000 and Korea Investment & Securities Co., Ltd., Investment Arm for KRW 500,000,000. The company issued bonds at par. The bonds carry fixed interest rate of 3% per annum and yield to maturity of 3%. The bonds will mature on March 12, 2021. The bonds are convertible into 165,975 common shares of the company at a fixed conversion price of KRW 12,050 per share from March 12, 2019 to February 12, 2021. The transaction has been approved by the board of directors of the company.
DuChemBio Co Ltd is a Korea-based company principally engaged in the manufacture and sale of radiopharmaceuticals. The Company is engaged in the manufacture and sale of diagnostic radiopharmaceuticals such as radiopharmaceuticals for the diagnosis of Parkinson's disease, radiopharmaceuticals for the diagnosis of Alzheimer's disease, and radiopharmaceuticals for the diagnosis of brain tumors. In addition, the Company is engaged in the sale of computed tomography (CT) contrast agents and other products.
DuChemBIO Co.,Ltd. announced that it has received KRW 2 billion in funding from Asam Asset Management Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm